[Influence of cefroxadine dry syrup on intestinal bacterial flora]. 1986

S Iwata, and T Yokota, and Y Kusumoto, and H Shiro, and Y Sato, and H Akita, and S Nanri, and T Oikawa, and S Kusano, and K Sunakawa

Influence of cefroxadine (CXD) dry syrup on intestinal bacterial flora was studied in mice infected with 4 species of bacteria, namely, Escherichia coli, Enterococcus faecalis, Bacteroides fragilis and Bifidobacterium breve, and in pediatric patients having infections in the respiratory tract and cutaneous/soft tissues. The results were summarized as follows: CXD dry syrup was administered for 5 consecutive days to mice infected with the 4 species. No considerable changes were observed in levels of bacteria in the feces and in different parts of digestive tracts. Eleven pediatric patients were orally administered with 30-54 mg/kg of CXD dry syrup a day for 7-15 consecutive days. Symptom of diarrhea was noted in 2 patients. Dominant species of the intestinal flora such as E. coli, Bifidobacterium, and Bacteroides sometimes decreased in patients treated with CXD dry syrup. In general, however, decreases in numbers of these bacteria were insignificant. Changes of intestinal flora in patients treated with CXD dry syrup were apparently smaller than those treated with ampicillin and were similar to those treated with cephalexin or amoxicillin.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007422 Intestines The section of the alimentary canal from the STOMACH to the ANAL CANAL. It includes the LARGE INTESTINE and SMALL INTESTINE. Intestine
D008297 Male Males
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D002515 Cephradine A semi-synthetic cephalosporin antibiotic. Anspor,Cefradine,Cephradine Dihydrate,Cephradine, Non-Stoichiometric Hydrate,Dexef,Kelsef,Maxisporin,Nicef,SQ-11436,Sefril,Septacef,Velocef,Velosef,Zeefra Gé,Cephradine, Non Stoichiometric Hydrate,Dihydrate, Cephradine,Non-Stoichiometric Hydrate Cephradine,SQ 11436,SQ11436
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004304 Dosage Forms Completed forms of the pharmaceutical preparation in which prescribed doses of medication are included. They are designed to resist action by gastric fluids, prevent vomiting and nausea, reduce or alleviate the undesirable taste and smells associated with oral administration, achieve a high concentration of drug at target site, or produce a delayed or long-acting drug effect. Dosage Form,Form, Dosage,Forms, Dosage
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D005260 Female Females

Related Publications

S Iwata, and T Yokota, and Y Kusumoto, and H Shiro, and Y Sato, and H Akita, and S Nanri, and T Oikawa, and S Kusano, and K Sunakawa
December 1981, The Japanese journal of antibiotics,
S Iwata, and T Yokota, and Y Kusumoto, and H Shiro, and Y Sato, and H Akita, and S Nanri, and T Oikawa, and S Kusano, and K Sunakawa
December 1981, The Japanese journal of antibiotics,
S Iwata, and T Yokota, and Y Kusumoto, and H Shiro, and Y Sato, and H Akita, and S Nanri, and T Oikawa, and S Kusano, and K Sunakawa
November 1992, The Japanese journal of antibiotics,
S Iwata, and T Yokota, and Y Kusumoto, and H Shiro, and Y Sato, and H Akita, and S Nanri, and T Oikawa, and S Kusano, and K Sunakawa
January 1992, The Japanese journal of antibiotics,
S Iwata, and T Yokota, and Y Kusumoto, and H Shiro, and Y Sato, and H Akita, and S Nanri, and T Oikawa, and S Kusano, and K Sunakawa
December 1966, Proceedings of the Royal Society of Medicine,
S Iwata, and T Yokota, and Y Kusumoto, and H Shiro, and Y Sato, and H Akita, and S Nanri, and T Oikawa, and S Kusano, and K Sunakawa
December 1981, The Japanese journal of antibiotics,
S Iwata, and T Yokota, and Y Kusumoto, and H Shiro, and Y Sato, and H Akita, and S Nanri, and T Oikawa, and S Kusano, and K Sunakawa
April 1968, Minerva pediatrica,
S Iwata, and T Yokota, and Y Kusumoto, and H Shiro, and Y Sato, and H Akita, and S Nanri, and T Oikawa, and S Kusano, and K Sunakawa
December 1981, The Japanese journal of antibiotics,
S Iwata, and T Yokota, and Y Kusumoto, and H Shiro, and Y Sato, and H Akita, and S Nanri, and T Oikawa, and S Kusano, and K Sunakawa
December 1981, The Japanese journal of antibiotics,
S Iwata, and T Yokota, and Y Kusumoto, and H Shiro, and Y Sato, and H Akita, and S Nanri, and T Oikawa, and S Kusano, and K Sunakawa
April 1961, Gaceta medica de Mexico,
Copied contents to your clipboard!